Beyond Analytical Validation: Is Your Sponsored Testing Program Ready to Launch?

An assay can meet its analytical performance criteria while the program around it still has unresolved launch questions. Can a provider place an order without assistance? What happens when a specimen arrives with missing information? Who notices when a result is late?

For a sponsored testing program, readiness deserves its own review. Precision BioStrategy recommends examining the complete path from the decision to order through delivery of the result—and assigning responsibility for the points where that path can break.

1. Connect the evidence to the clinical question

Begin with the decision the result is expected to support. Then ask whether the analytical documentation, specimen requirements, report format, and interpretation are aligned with that purpose.

A useful review distinguishes evidence already available from assumptions, limitations, and unanswered questions. Where relevant, examine the population studied, performance near decision points, method-comparison findings, and the basis for reference intervals. The depth of review should reflect the assay and its intended application.

The output should be a concise decision record: what is supported, what remains uncertain, and which questions need resolution before launch versus a defined follow-up plan. Analytical validation alone should not be treated as proof of clinical utility or overall program readiness.

2. Walk the complete specimen journey

Map ordering, collection, transport, receipt, accessioning, testing, review, and report delivery. At each handoff, identify the required information, responsible party, and response when something is missing.

For example, a technically acceptable specimen may still encounter an administrative hold. A report may be released successfully but fail to reach the intended recipient. A launch review should ask the team to demonstrate these workflows rather than rely only on a description of the standard process.

Use a small set of realistic scenarios: a routine order, an incomplete requisition, an unsuitable specimen, and a delayed shipment. Confirm the collection and shipping instructions against the laboratory’s accepted conditions. Provider guidance should describe the actual workflow and available options without creating unsupported promises.

3. Define turnaround time before promising it

“Five days” is not a complete service definition. Does the clock begin at collection, receipt at a local facility, or accessioning at the testing laboratory? Does it stop at result authorization or delivery? Are days calendar days or business days?

PBS recommends documenting the start, stop, exclusions, and escalation trigger together. Distinguish the laboratory’s processing commitment from the total time experienced by the ordering provider.

Where suitable data are available, review the median, the 90th percentile, and the proportion meeting the agreed target. Define the eligible population and calculation rules. Completed-result metrics should be paired with visibility into overdue pending specimens; a completed-only report cannot describe every specimen still waiting for a result.

4. Design reporting around decisions

Choose metrics by asking what action each one enables. Order volume can inform uptake. Rejection reasons can identify collection problems. Receipt and release timestamps can support turnaround analysis. An aging view of pending specimens can guide escalation.

Separate patient-level clinical reporting from sponsor-level program oversight. Agree on the permitted data, appropriate aggregation, access controls, delivery cadence, and accountable recipients. Request only the information needed for the oversight task.

Before launch, inspect an example report or agreed specification. Confirm how cancellations, insufficient specimens, repeat testing, and unresolved cases will be represented. A reporting commitment is more useful when the team understands both its coverage and its blind spots.

5. Give open issues an owner and a decision rule

A list of concerns becomes actionable when every item has an owner, due date, and closure criterion. Separate launch dependencies from improvements that can follow under an agreed plan.

For each issue, record the consequence if it remains unresolved and the evidence needed to close it. Some answers may require clarification or documentation; others may require workflow changes or additional studies. The response should follow the nature of the gap.

A readiness meeting should end with explicit decisions and recorded ownership. The program should also have a named escalation route for problems that cross organizational boundaries.

A practical launch-readiness check

These questions form a practical review framework, not a universal pass/fail standard. The aim is to make the scientific and operational basis for launch visible enough for responsible teams to make and document their decisions.